Sagimet Biosciences (SGMT) Equity Average (2022 - 2026)
Sagimet Biosciences' Equity Average history spans 5 years, with the latest figure at $106.9 million for Q1 2026.
- Quarterly Equity Average fell 27.46% to $106.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $106.9 million through Mar 2026, down 27.46% year-over-year, with the annual reading at $133.6 million for FY2025, 8.23% up from the prior year.
- Equity Average came in at $106.9 million for Q1 2026, down from $115.3 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $186.7 million in Q2 2024 to a low of -$195.6 million in Q2 2023.
- The 5-year median for Equity Average is $115.3 million (2025), against an average of $39.6 million.
- Year-over-year, Equity Average surged 452.08% in 2024 and then decreased 29.54% in 2025.
- Sagimet Biosciences' Equity Average stood at -$183.8 million in 2022, then soared by 151.41% to $94.5 million in 2023, then surged by 72.8% to $163.2 million in 2024, then dropped by 29.36% to $115.3 million in 2025, then fell by 7.28% to $106.9 million in 2026.
- Per Business Quant, the three most recent readings for SGMT's Equity Average are $106.9 million (Q1 2026), $115.3 million (Q4 2025), and $124.7 million (Q3 2025).